ライフサイエンスコーパス: drug user

1 e inhibitors for relapse prevention in human drug users.

2 drug use and its consequences in established drug users.

3 esis of HCV-related fibrosis among injection drug users.

4 on and clearance among a cohort of injection drug users.

5 ve parity in health outcomes in HIV-infected drug users.

6 m, HIV-induced disease may be more severe in drug users.

7 2%, men who have sex with men, and injection drug users.

8 ction that has recently been associated with drug users.

9 dered to be primarily a disease of injection drug users.

10 during natural childbirth, and in injection drug users.

11 itis is not primarily a disease of injection drug users.

12 nce, and 11 comparison subjects who were not drug users.

13 ion in this cohort of HCV-infected injection drug users.

14 ss people, migrants, refugees, prisoners, or drug users.

15 18 to 35 who were crack cocaine or injecting drug users.

16 tion risk behavior among depressed injection drug users.

17 e health and social outcomes among injection drug users.

18 related deaths in Scotland per 100 injecting drug users.

19 injection HIV risk behavior among injection drug users.

20 opic virus type II (HTLV-II) is common among drug users.

21 would be significantly higher among illicit drug users.

22 oup per 1000 population or per 100 injecting drug users.

23 CV infection and persistence among injecting drug users.

24 nt of chronic viral diseases among injection drug users.

25 pertise in treating hepatitis and caring for drug users.

26 ted States, and most new infections occur in drug users.

27 dness-of-fit, to model networks of injection drug users.

28 virus (HIV)-positive and 46 687 HIV-negative drug users.

29 tion is common in hemophiliacs and injection drug users.

30 to an understanding of the behavior of human drug users.

31 se with prior MRSA exposure, and intravenous drug users.

32 lso been described in monoinfected injecting drug users.

33 xually transmitted infection), and injection drug users.

34 als, serodiscordant couples, and intravenous drug users.

35 abis and ecstasy, is usual among experienced drug users.

36 fficult-to-reach populations such as problem drug users.

37 n, heterosexual men and women, and injecting drug users.

38 ding men who have sex with men and injection drug users.

39 of HCV- and HIV-negative, active intravenous drug users.

40 on-relevant biomarkers in current and former drug users.

41 in high, especially in young adult injection drug users.

42 docarditis (IE) is rare, even in intravenous drug users.

43 .90-1.11) for nonsteroidal anti-inflammatory drug users, 0.97 (95% CI, 0.82-1.14) for glucocorticoid

44 n female (0.9 [95% CI 0.6-1.1]) than in male drug users (1.5; 1.3-1.7).

45 proportion of sex workers who are injecting drug users (-1.93; p=0.026).

46 with men, 0.38/100 PY among male intravenous drug users, 1.24/100 PY among female intravenous drug us

47 Among prescription drug users, 16% also took an herbal/supplement; the rate

48 .8-22.9%) for nonsteroidal anti-inflammatory drug users, 17.4% (95% CI, 15.4-19.5%) for glucocorticoi

49 id-1990s), or corresponding data for problem drug users (21% older than 34 years in 2000) to compare

50 men (2.7; 1.7-4.2), and being an intravenous drug user (3.8; 2.4-6.1) were all associated with a high

51 e (38.3% versus 27.1%), less often injection drug users (3.2% versus 9.5%) or men who have sex with m

52 bacteremia were more likely to be injection drug users (61% versus 15%; P < 0.001), to have right-si

53 , most were asymptomatic (64%) and injection drug users (66%).

54 an age, 42 years; 81% males; 46% intravenous drug users, 85.4% on ART) were analyzed.

55 xual people (2.94, 2.28-3.73); 203 injecting drug users (9.37, 8.13-10.75); and 30 in the other or un

56 reported alcohol drinkers (77%), and illicit drug users (90%).

57 Chronic drug users account for a third of all cases of AIDS in t

58 Injecting drug users accounted for 49% of CA-MRSA infections but o

59 nine, can be detected in fingerprints of non-drug users after contact with cocaine.

60 Injecting drug users' age distribution should be assessed and comp

61 ears, depending on whether current injecting drug users' age distribution was assumed to be the same

62 poral cortex, and in the locus coeruleus, of drug users aged > 30 years (all P = 0.04).

63 d AIDS risks of 16.75% among 1,143 injection drug users and 12.08% among 6,039 nonusers, yielding a s

64 sis of HBV and HCV incidence among injecting drug users and country-level data on the incidence of HB

65 ally and prevalent specifically in injecting drug users and hemophiliacs.

66 rculosis identification and management among drug users and homeless people.

67 High-risk (injection drug users and men who have sex with men) and low-risk p

68 escribed HCV occurring among young injection drug users and men who have sex with men.

69 tablished clusters predominated by injection drug users and more-recently emerging clusters comprisin

70 that were similar to those of HCV injection drug users and were significantly higher than in nonuser

71 ture longitudinal research on newly incident drug users and with tracking of self-administration freq

72 users, 1.24/100 PY among female intravenous drug users, and 1.13/100 PY among women at heterosexual

73 d cues elicit conditioned responses in human drug users, and are thought to facilitate a drug-seeking

74 Blacks, Latinos, intravenous drug users, and less educated individuals need advance c

75 rable to that seen in clinical trials of non-drug users, and the rate of HCV reinfection is low.

76 V-2 infection is prevalent among intravenous drug users, and the viral genome encodes the viral trans

77 sex with men, heterosexual people, injecting drug users, and those at other or unknown risk.

78 pecially younger patients, Asians, injection drug users, and those with an increased number of lifeti

79 ividuals of indigenous background, injection drug users, and those with psychiatric disorder.

80 of past-year ayahuasca users and comparison drug users; and subjective effects of ayahuasca and comp

81 Injecting drug users are a high-risk group for hepatitis B virus (

82 ferent populations, but data among injection drug users are limited.

83 acteristics as derived from a set of 170,097 drug users are provided as part of SMARTS and can be use

84 andard schedule (66%; P = .04), although for drug users as a whole the corresponding adherence rates

85 study of Baltimore City, Maryland, injection drug users assessed between 1990 and 2006.

86 cs in a seroincidence study of 263 injection drug users at high risk of human immunodeficiency virus

87 Second, covariates for drug users at study entry often are plausibly affected b

88 l of whom were current or previous injecting drug users at the time of enrolment in the BTS, were off

89 problem that is more prevalent in injection drug users because they have a higher risk for acquiring

90 We profiled plasma miRNAs in injection drug users before, during, and (in the people with resol

91 Single hair samples from drug users, blank hairs, and zolpidem- and zolpidem-D6-s

92 ta amyloid (AB4, AB42 and 4G8) was raised in drug user brains (mainly as shadow plaques) but not sign

93 hyperphosphorylated tau and beta amyloid in drug user brains allows comparison with the related path

94 that deposits of hyperphosphorylated tau in drug user brains exceed those seen in age-matched contro

95 phosphorylating enzyme, GSK-3, was raised in drug user brains.

96 th three- and four-repeat tau was present in drug user brains.

97 ly (P = 0.038) with microglial activation in drug users but not in controls.

98 udies have shown that even current injection drug users can be treated successfully with results comp

99 In conclusion, ACC hypoactivations in drug users cannot be attributed to task difficulty or di

100 in the Montreal Acute Hepatitis C Injection Drug User Cohort Study who were reinfected with HCV from

101 ch HCV transmission occurs between injection drug user communities in London, Edinburgh, Glasgow (Uni

102 A total of 644 young (<30 years) injection drug users completed a baseline interview and were enrol

103 here is little precedent for offering active drug users complex treatments for depression.

104 Injection drug users constitute the largest group of persons infec

105 Injection drug users consumed less energy than did nonusers.

106 Injecting drug users could be a major reservoir for CA-MRSA transm

107 ought heretofore elusive evidence that human drug users could show additive (or more-than-additive) e

108 Drug users demonstrated significant attentional bias for

109 rds of regular nonsteroidal antiinflammatory drug users develop subclinical small bowel enteropathy.

110 mprove HCV preventive services for injection drug users; develop a hepatitis C vaccine; and prevent H

111 with HCV were classified as either injection drug users, drinkers, or nonusers based on questionnaire

112 recruited cohort of HIV-seropositive illicit drug users during a community-wide ART expansion interve

113 on was significantly higher for intermittent drug users during periods of active use (odds ratio = 2.

114 Hepatitis C virus (HCV)-infected drug users (DUs) have largely been excluded from HCV car

115 Drug users (DUs), a population that accounts for some of

116 tudy-visit specimens obtained from injection drug users enrolled in a longitudinal cohort study of HI

117 Across 5 studies (comprising 131 drug users) examining reinfection, pooled risk was 2.4 (

118 The Prescription Drug User Fee Act (PDUFA) imposes deadlines for the comp

119 The amount of Prescription Drug User Fee Act fees collected from industry increased

120 upcoming reauthorization of the Prescription Drug User Fee Act focuses on improving the review proces

121 84 from 1985 to the enactment of the Generic Drug User Fee Act in 2012; and 588 from 2013-2018.

122 Prescription drug user fee funding expanded from new drugs and biolog

123 The levels of hyperphosphorylated tau in drug users fell far short of those seen in Alzheimer's d

124 related deaths, but those based on injecting drug users fitted tolerably.

125 ing 39 human immunodeficiency virus negative drug users, five subjects with Alzheimer's disease and 3

126 e Intravenous Experience cohort of injection drug users, frequencies of three correlated SNPs coverin

127 t determinants of HIV infection in injecting drug users from 2000 to 2009, classifying findings by ty

128 ction and load in a cohort of 6570 injection drug users from 9 US cities during 1987-1991.

129 y perspective on research, stigmatization of drug users from research and the absence of the 'moral v

130 e long-distance dispersion among intravenous drug users from the northwest.

131 oeconomic position" (group 4) and "injection drug users" (group 8).

132 Women injecting drug users had a higher HCV risk than did men (odds rati

133 ed with men who have sex with men, injection drug users had a statistically significantly increased r

134 However, HIV/HCV injection drug users had HCV-specific IFN- gamma and IL-10 respons

135 Compared with control subjects, drug users had higher [11C]-(+)-PHNO binding in the D3-r

136 younger adults, women, blacks, and injection drug users had poorer outcomes.

137 y contrast with the pre-HAART era, injecting drug users had significantly higher mortality in 1999-20

138 drugs of abuse could be detected in a single drug user hair scan with confirmation of identity by bot

139 In fact, opioid drug users have an increased risk of developing neurocog

140 HIV-infected drug users have increased age-matched morbidity and mort

141 from identification of factors that prevent drug users' heavy reliance on inpatient care; however, o

142 of both patients' residences, and injection drug user (IDU) contacts of the 2012 patient.

143 many other persons, per annum, an injection drug user (IDU) has the equivalent of full responsibilit

144 Twenty-two active injection drug users (IDU) who had cleared a primary hepatitis C v

145 n men who have sex with men (MSM), injection drug users (IDU), and heterosexuals (HET).

146 dministration (VA) patients, young injection drug users (IDU), and older IDU, were screened for HCV R

147 umbers of paid blood donors (PBD), injection drug users (IDU), and sexual partners of infected indivi

148 n men who have sex with men (MSM), injecting drug users (IDU), female sex workers (FSW) and heterosex

149 coccal disease in HIV-seropositive injection drug users (IDU), we utilized a prospective cohort of ID

150 th men, males with hemophilia, and injection drug users (IDUs) (n = 1865).

151 iciency virus type 1 (HIV-1) among injecting drug users (IDUs) are spreading in China along heroin tr

152 providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non-IDUs

153 Previous studies suggest that most injection drug users (IDUs) become infected with hepatitis C virus

154 ropolitan Administration cohort of injecting drug users (IDUs) consisted of 1,209 IDUs initially sero

155 In all, 1905 injection drug users (IDUs) enrolled in a cross-sectional study we

156 or female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and f

157 Surprisingly, a recent study of injection drug users (IDUs) from St.

158 1-positive street-recruited active injection drug users (IDUs) from the San Francisco Bay area.

159 ethnicity-stratified sample of 531 injection drug users (IDUs) from the San Francisco Bay area.

160 Of 397 injection drug users (IDUs) in Baltimore, Maryland, SENV-D infecti

161 Study, a community-based cohort of injection drug users (IDUs) in Baltimore, Maryland, with a focus o

162 Young injection drug users (IDUs) in San Francisco may be at high risk f

163 ) incidence among street-recruited injection drug users (IDUs) in San Francisco, California, from 198

164 ciency virus (HIV) infection among injection drug users (IDUs) in Taiwan.

165 ors of death among male and female injection drug users (IDUs) in Vancouver, British Columbia, Canada

166 f antiretroviral therapy (ART) for injecting drug users (IDUs) infected with HIV, with particular att

167 Injection drug users (IDUs) on the accelerated schedule were signi

168 onstrated in peripheral blood from injection drug users (IDUs) persistently HCV antibody and RNA nega

169 and HCV infection prevalence among injection drug users (IDUs) recruited over 4 periods: 1988-1989, 1

170 bacterial endocarditis in febrile injection drug users (IDUs) remains problematic because of delays

171 tis B virus (HBV) infections among injection drug users (IDUs) resulting in several deaths.

172 opositive and 920 HIV-seronegative injection drug users (IDUs) were followed from 1997 to 2000.

173 7 hepatitis C virus (HCV)-infected injection drug users (IDUs) were selected for liver biopsy procedu

174 numbers of both current and former injecting drug users (IDUs) who acquired HCV and progressed to mod

175 erized CD56(pos) populations in 11 injection drug users (IDUs) who remained uninfected despite being

176 Injection drug users (IDUs) who successfully clear hepatitis C vir

177 cohort of recently infected young injection drug users (IDUs) with an HCV incidence rate of 25%.

178 en who have sex with men (MSMs), intravenous drug users (IDUs), hepatitis C virus (HCV)-infected and

179 is C virus (HCV) seroconversion in injection drug users (IDUs), some have questioned whether underrep

180 infective endocarditis (IE) among injection drug users (IDUs), the incidence of IE was determined ac

181 nd reinfection are best studied in injection drug users (IDUs), who have the highest incidence of HCV

182 in an ethnically diverse group of injection drug users (IDUs).

183 HCV infections are transmitted via injecting drug users (IDUs).

184 le of 210 out of 1667 HCV-positive injection drug users (IDUs).

185 rus (HIV) and risk behaviors among injection drug users (IDUs).

186 virus (HCV) infection among young injection drug users (IDUs).

187 f HCV infection in most samples of injection drug users (IDUs).

188 V-1 infections in the USA occur in injection drug users (IDUs).

189 Sixty-two percent were former injecting drug users (IDUs).

190 on mortality in a cohort of aging injection drug users (IDUs).

191 ciated with syringe purchase among injection drug users (IDUs).

192 occurred in 46% of MSM (49% in non-injection drug users [IDUs] and 23% in IDUs).

193 ruses (95% in HCV-HIV coinfected intravenous drug users [IDUs]).

194 Among injection drug users, IL18 -607A (odds ratio [OR], 3.68 [95% confi

195 trolled trial among not-in-treatment current drug users in 2 urban neighborhoods.

196 .31) of the global population were injection drug users in 2017, and 8% (5-12) of prevalent HCV infec

197 Injection drug users in Baltimore, Maryland, who were positive for

198 a high-risk cohort composed of 188 injection drug users in Baltimore, Maryland.

199 ce use of drug-user registries, detention of drug users in centres offering no evidence-based treatme

200 produced 5 estimates of the number of heavy drug users in Curitiba, Brazil.

201 unlinked anonymous surveillance of injecting drug users in England and Wales.

202 arch and the absence of the 'moral voice' of drug users in ethical decision-making.

203 the scope of metacognition impairment among drug users in general and opiate dependent individuals i

204 d risk characteristics among young injection drug users in San Francisco, California, and compared th

205 03(9.0%) of 4498 heterosexuals and injection drug users in Shenzhen, China from 2005-2012.

206 ttle is known about remission patterns among drug users in the community.

207 also apply the method to data from injecting drug users in Ukraine.

208 same as problem drug users' or as injecting drug users' in the mid-1990s (2.1 [1.7-2.5] or 5.3 [4.3-

209 Tuberculosis co-infection in HIV-infected drug users, including disease caused by drug-resistant s

210 kelihood of using organs from an intravenous drug user increased from 12.5% (4/24) with serology nega

211 nts with bleeding disorders and 44 injecting drug users, infection by more than one HCV genotype was

212 hors conducted a large-scale cohort study of drug users initially free of persistent psychosis.

213 rug abuse care with regular medical care for drug users is associated with less subsequent hospitaliz

214 nterventions to stop the spread of HCV among drug users is critical.

215 eural basis of altered social interaction in drug users is currently unknown.

216 bacco smoking among HIV-infected intravenous drug users (IVDUs), we set out to study the effects of s

217 Social interaction deficits in drug users likely impede treatment, increase the burden

218 abnormalities are common symptoms in chronic drug users long after drug withdrawal.

219 lying the most clinically relevant decisions drug users make: decisions to use drugs.

220 The high prevalence of HCV among injection drug users may be partly due to the resilience of the vi

221 Similarly, injection drugs users may come into contact with fomites.

222 e of hepatitis C virus (HCV) among injection drug users might be due to prolonged virus survival in c

223 nt of multiple comorbidities in HIV-infected drug users might result in complex pharmacokinetic drug

224 ticipants (gay men (n = 1,974) and injection drug users (n = 903)) were randomly assigned to either A

225 rug users (N=861), and past-year symptomatic drug users (N=1,117).

226 shed regional estimates of current injecting drug users (n=22805), their sex (30% female) and age dis

227 nonusers (N=32,675), past-year asymptomatic drug users (N=861), and past-year symptomatic drug users

228 Among 27 705 past-year alcohol or drug users, Native Americans (31.5%), adolescents of mul

229 ion programs that target depressed injection drug users need to be designed.

230 HIV Behavioral Surveillance System-Injection Drug Users (NHBS-IDU2, 2009), we developed multivariate

231 dence interval: 1.4, 2.9) and for persistent drug users (odds ratio = 1.9, 95% confidence interval: 1

232 Across 6 studies (comprising 314 drug users, of whom 141 [45%] were PWID), pooled SVR was

233 nd six times more frequent per 100 injecting drug users older than 34 years than younger than 25 year

234 greater propensity to habitual behaviour in drug users or as a function of dependence severity, and

235 HCV infected "high-risk" patients (injecting drug users or prisoners); (3) human immunodeficiency vir

236 bution was assumed to be the same as problem drug users' or as injecting drug users' in the mid-1990s

237 pairs, 2,886 nonsteroidal anti-inflammatory drug user pairs, 1,440 glucocorticoid user pairs, and 1,

238 ocorticoid user pairs, and 1,743 combination drug user pairs.

239 e B strains, which occurred in two injection drug users participating in a prospective cohort study i

240 with either HIV infection or AIDS, injection drug users, patients with abscesses, and those recently

241 idence interval, -554 to -148) per specialty-drug user per month, representing a 32% reduction in spe

242 human immunodeficiency virus and intravenous-drug user populations are also causes for concern.

243 (eg, health-care professionals or injecting drug users) previously known to be seronegative.

244 nce fluctuated substantially over time among drug users recruited from the community.

245 tudies of young (aged 18-30 years) injecting drug users recruited in 1997-1999 in the Harlem and Lowe

246 an immunodeficiency virus-infected injection drug users recruited into the Acquired Immunodeficiency

247 Participants were 1,339 injection drug users recruited into the AIDS Link to Intravenous E

248 of harmful policies--including police use of drug-user registries, detention of drug users in centres

249 In abstinent drug users, relapse is often precipitated by re-exposure

250 2%), trauma/accidents (10.5%), and injection drug user-related medical conditions (13.1%).

251 imal health care delivery models for illicit drug users remain ill-defined.

252 The treatment of hepatitis C in drug users requires an interdisciplinary approach that b

253 ot seem to arise solely as a result of young drug users' seeking out opportunities to use drugs.

254 oing a serious HIV-1 epidemic in intravenous drug users, sex workers, and former plasma donors.

255 We conclude that drug users show early Alzheimer's disease-related brain

256 Under the age of 30 years, drug users showed a similar increase in neuropil threads

257 t cocaine at a dose within the range used by drug users significantly increases the [Ca(2+)](i) in th

258 ransmission and transmission among injecting drug users, started now, could avert 28 million new HIV

259 ta were derived from the Vancouver Injection Drug Users Study.

260 analysis including a population of injection drug users suggests a codominant mode of inheritance of

261 uropil threads increased at a faster rate in drug users than in controls and the levels of the phosph

262 conomic status and the presence of injection drug users, that were independently associated with HSV-

263 In HIV-positive drug users, the adjusted odds ratio (AOR) for hospitaliz

264 In HIV-negative drug users, the AOR of hospitalization was lower for tho

265 changes can lead to psychiatric illnesses in drug users, the evidence that we show in our study sugge

266 V, particularly among HIV-infected injection drug users, the rate of incident HIV infections is incre

267 is most commonly transmitted among injection drug users, the role of sexual transmission in the sprea

268 The outbreak began among intravenous drug users then spread to the general population.

269 ly the result of needle sharing by injection drug users, therefore appears to be frequently initiated

270 r drugs, to have had sex with an intravenous drug user, to have sex when "high" on alcohol or drugs,

271 us-positive man who is an active intravenous drug user together with review of all published cases.

272 From a study of injecting drug users, we identified 164 people who had no evidence

273 Older and male injecting drug users were at highest risk of drug-related death.

274 an immunodeficiency virus-negative injection drug users were enrolled prospectively and followed mont

275 ople 40 years of age or older, and injection drug users were overrepresented among deaths ascertained

276 An additional 338 HIV-negative drug users were recruited in 1994 and were studied by us

277 rug-related deaths in 2001 per 100 injecting drug users were significantly lower in female (0.9 [95%

278 ces obtained from 154 HCV-infected injection drug users were studied to determine the extent to which

279 Decreased D2 receptor densities in drug users, whether premorbid or the consequence of subs

280 ies have confirmed decreased D2 receptors in drug users, which is associated with increased salience

281 present a case of a 43-year-old intravenous drug user who developed A. israelii infection in connect

282 regress to normal levels in former injection drug users who are HCV aviremic.

283 , men who have sex with men, and intravenous drug users who are HIV infected yet susceptible to HBV,

284 I coinfection in a cohort of 6,570 injection drug users who enrolled in 9 US cities between 1987 and

285 ha-based therapy and the second was 251 i.v. drug users who had either spontaneously cleared HCV or b

286 se in young, often suburban heroin injection drug users who initiate use with oral prescription opioi

287 Injection drug users who met the DSM-IV criteria for major depress

288 No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial)

289 ial risk of HCV transmission among injection drug users who share water, filters, and water container

290 x months in 156 male and 46 female injection-drug users who were followed prospectively after HIV-1 s

291 ge in out-of-pocket spending among specialty-drug users who were in the 95th percentile for spending

292 negatively affect the health of HIV-infected drug users, who also have frequent medical and psychiatr

293 s will respond to treatment, which abstinent drug users will relapse, or which patients will convert

294 Our findings demonstrate that active drug users with dual diagnoses are able to participate i

295 s performed among African American injection drug users with HCV clearance (n = 91) or HCV persistenc

296 atients with positive results were injection drug users with potential multiple HCV exposures.

297 re studied prospectively in active injection drug users with recurrent HCV RNA-positive tests after s

298 USA300 strains were more common in injection drug users with skin/wound as the predominant source of

299 6% of HIV-positive and 37.5% of HIV-negative drug users, with a mean of 27.5 and 24.5 inpatient days,

300 geted screening, particularly in intravenous drug users, would be substantially higher than in the ge